Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhaseRx Inc.

www.phaserx.com

Latest From PhaseRx Inc.

Finance Watch: Rhythm And OptiNose IPOs Bring 2017 Total To 31, Surpassing 2016

Public Company Financings: Rhythm and OptiNose are the 30th and 31st initial public offerings of 2017. Also, reverse mergers add two more newly public firms, Valeant raises $1bn to pay down more debt, and PhaseRx and Trevena cut jobs.

Financing Business Strategies

PhaseRx Makes More Noise Than Silence With mRNA Delivery

Having ditched silence RNA in 2012, PhaseRx president and CEO Dr Robert Overell explains to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how delivering messenger RNA inside diseased cells may revolutionize and grow the current $4bn enzyme replacement market.

Research & Development Research and Development Strategies

US IPOs In Review: Relatively Muted Market In 2016 To Continue In 2017

After biopharma initial public offerings in the US during 2016 outperformed the prior year’s IPOs, expect more of the same in 2017: fewer, but higher quality offerings at lower IPO share prices to keep values at acceptable levels for experienced health care investors.

StartUps and SMEs Financing

IPO Update: TiGenix Debuts In December After Motif Launched In November As 2016 Offerings Best 2015

Motif Bio and TiGenix were the 29th and 30th biopharma IPOs in 2016 with the only first-time offerings for November and so far in December, but looking at performance so far this year, IPOs by therapeutics firms in 2016 continue to outperform 2015 offerings.

Commercial Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Hepatic (Liver)
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • PhaseRx Inc.
  • Senior Management
  • Robert Overell, PhD, Pres. & CEO
    Michael Houston, PhD, CSO
    Helen Tsui, VP, Fin.
    Gordon Brandt, MD, CMO
  • Contact Info
  • PhaseRx Inc.
    Phone: (206) 805-6300
    410 W. Harrison St.
    Ste. 300
    Seattle, WA 98119
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register